MacroGenics can serve as a high-potential addition for aggressive growth portfolios focused on cutting-edge oncology and antibody-drug conjugate technologies. Because the company experiences financial fluctuations typical of pre-commercial biotech firms—including periodic net operating losses and reliance on milestone licensing payments—it requires careful risk assessment. Investors must weigh its scientific pipeline potential against potential clinical setbacks and market sentiment shifts before deploying capital.